PartnershipJul 13, 2026, 08:37 AM
Ocugen Licenses OCU400 Gene Therapy for MENA; Up to $255M Sales Milestones
AI Summary
Ocugen, Inc. announced a binding term sheet with Roots Pharmaceutical and Al-Dhow International Holding to license its OCU400 modifier gene therapy for Retinitis Pigmentosa in the Middle East and North Africa (MENA) region. Under the agreement, Ocugen is set to receive up to $4 million in upfront and near-term development milestones, up to $255 million in sales milestones, and a 22% royalty on net sales. Ocugen will also manufacture and supply OCU400. The definitive agreement is anticipated within 90 days, while OCU400 continues its Phase 3 clinical development with a topline readout expected in Q1 2027.
Key Highlights
- Signed binding term sheet to license OCU400 gene therapy in MENA region.
- Partnered with Roots Pharmaceutical and Al-Dhow International Holding.
- Upfront and near-term development milestones up to $4 million.
- Sales milestones up to $255 million.
- Royalty of 22% on net sales of OCU400.
- Ocugen to manufacture and supply OCU400.
- Definitive agreement expected within 90 days.
- OCU400 Phase 3 topline readout anticipated in Q1 2027.
Price Impact
More from OCGN